根据ESI于2025年9月发布的数据，我校高被引论文（Highly Cited Papers）634篇，热点论文（Hot Papers）28篇，见附件：2025年9月南方医科大学高被引论文及热点论文简表。详情如下。
从学科角度看，在634篇高被引论文中，临床医学最多（321篇），占比50.63%，药理学与毒理学51篇（8.04%）紧跟其后。
|
序号 |
高被引论文 Research Field |
2025.9 |
2025.7 |
||
|
论文数 |
占比 |
论文数 |
占比 |
||
|
１ |
CLINICAL MEDICINE |
321 |
50.63% |
303 |
49.92% |
|
2 |
MOLECULAR BIOLOGY & GENETICS |
44 |
6.94% |
43 |
7.08% |
|
3 |
BIOLOGY & BIOCHEMISTRY |
44 |
6.94% |
39 |
6.43% |
|
4 |
PHARMACOLOGY & TOXICOLOGY |
51 |
8.04% |
50 |
8.24% |
|
5 |
MATERIALS SCIENCE |
37 |
5.84% |
41 |
6.75% |
|
6 |
NEUROSCIENCE & BEHAVIOR |
22 |
3.47% |
22 |
3.62% |
|
7 |
ENGINEERING |
11 |
1.74% |
11 |
1.81% |
|
8 |
MICROBIOLOGY |
17 |
2.68% |
16 |
2.64% |
|
9 |
CHEMISTRY |
9 |
1.42% |
10 |
1.65% |
|
10 |
PHYSICS |
22 |
3.47% |
17 |
2.80% |
|
11 |
PSYCHIATRY/PSYCHOLOGY |
13 |
2.05% |
13 |
2.14% |
|
12 |
IMMUNOLOGY |
12 |
1.89% |
13 |
2.14% |
|
13 |
SOCIAL SCIENCES, GENERAL |
9 |
1.42% |
7 |
1.15% |
|
14 |
COMPUTER SCIENCE |
8 |
1.26% |
8 |
1.32% |
|
15 |
AGRICULTURAL SCIENCES |
5 |
0.79% |
5 |
0.82% |
|
16 |
MULTIDISCIPLINARY |
1 |
0.16% |
1 |
0.16% |
|
17 |
ENVIRONMENT/ECOLOGY |
7 |
1.10% |
7 |
1.15% |
|
18 |
MATHEMATICS |
1 |
0.16% |
1 |
0.16% |
|
|
合计 |
634 |
100.00% |
607 |
100.00% |
|
序号 |
2025年9月我校28篇热点论文 标题 |
来源期刊 |
DOI |
Research Field |
Times Cited |
|
1 |
MINIMAL INFORMATION FOR STUDIES OF EXTRACELLULAR VESICLES (MISEV2023): FROM BASIC TO ADVANCED APPROACHES |
JOURNAL OF EXTRACELLULAR VESICLES 13 (2): - FEB 2024 |
10.1002/jev2.12404 |
BIOLOGY & BIOCHEMISTRY |
1213 |
|
2 |
GLOBAL BURDEN OF 288 CAUSES OF DEATH AND LIFE EXPECTANCY DECOMPOSITION IN 204 COUNTRIES AND TERRITORIES AND 811 SUBNATIONAL LOCATIONS, 1990-2021: A SYSTEMATIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2021 |
LANCET 403 (10440): 2100-2132 MAY 18 2024 |
10.1016/S0140-6736(24)00367-2 |
CLINICAL MEDICINE |
717 |
|
3 |
GLOBAL BURDEN AND STRENGTH OF EVIDENCE FOR 88 RISK FACTORS IN 204 COUNTRIES AND 811 SUBNATIONAL LOCATIONS, 1990-2021: A SYSTEMATIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2021 |
LANCET 403 (10440): 2162-2203 MAY 18 2024 |
10.1016/S0140-6736(24)00933-4 |
CLINICAL MEDICINE |
673 |
|
4 |
GLOBAL INCIDENCE, PREVALENCE, YEARS LIVED WITH DISABILITY (YLDS), DISABILITY-ADJUSTED LIFE-YEARS (DALYS), AND HEALTHY LIFE EXPECTANCY (HALE) FOR 371 DISEASES AND INJURIES IN 204 COUNTRIES AND TERRITORIES AND 811 SUBNATIONAL LOCATIONS, 1990-2021: A SYSTEMATIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2021 |
LANCET 403 (10440): 2133-2161 MAY 18 2024 |
10.1016/S0140-6736(24)00757-8 |
CLINICAL MEDICINE |
601 |
|
5 |
CAMRELIZUMAB PLUS RIVOCERANIB VERSUS SORAFENIB AS FIRST-LINE THERAPY FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA (CARES-310): A RANDOMISED, OPEN-LABEL, INTERNATIONAL PHASE 3 STUDY |
LANCET 402 (10408): 1133-1146 SEP 30 2023 |
10.1016/S0140-6736(23)00961-3 |
CLINICAL MEDICINE |
358 |
|
6 |
BURDEN OF DISEASE SCENARIOS FOR 204 COUNTRIES AND TERRITORIES, 2022-2050: A FORECASTING ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2021 |
LANCET 403 (10440): 2204-2256 MAY 18 2024 |
10.1016/S0140-6736(24)00685-8 |
CLINICAL MEDICINE |
235 |
|
7 |
GLOBAL, REGIONAL, AND NATIONAL BURDEN OF STROKE AND ITS RISK FACTORS, 1990-2021: A SYSTEMATIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2021 |
LANCET NEUROLOGY 23 (10): 973-1003 OCT 2024 |
10.1016/S1474-4422(24)00369-7 |
NEUROSCIENCE & BEHAVIOR |
172 |
|
8 |
USING CLUSTERPROFILER TO CHARACTERIZE MULTIOMICS DATA |
NATURE PROTOCOLS 19 (11): - NOV 2024 |
10.1038/s41596-024-01020-z |
BIOLOGY & BIOCHEMISTRY |
154 |
|
9 |
ALECTINIB IN RESECTED <I>ALK</I>-POSITIVE NON-SMALL-CELL LUNG CANCER |
NEW ENGLAND JOURNAL OF MEDICINE 390 (14): 1265-1276 APR 11 2024 |
10.1056/NEJMoa2310532 |
CLINICAL MEDICINE |
139 |
|
10 |
GLOBAL FERTILITY IN 204 COUNTRIES AND TERRITORIES, 1950-2021, WITH FORECASTS TO 2100: A COMPREHENSIVE DEMOGRAPHIC ANALYSIS FOR THE GLOBAL BURDEN OF DISEASE STUDY 2021 |
LANCET 403 (10440): 2057-2099 MAY 18 2024 |
10.1016/S0140-6736(24)00550-6 |
CLINICAL MEDICINE |
128 |
|
11 |
THE CHINESE SOCIETY OF CLINICAL ONCOLOGY (CSCO): CLINICAL GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF GASTRIC CANCER, 2023 |
CANCER COMMUNICATIONS : - DEC 31 2023 |
10.1002/cac2.12516 |
CLINICAL MEDICINE |
119 |
|
12 |
EVALUATION AND TREATMENT OF KNEE PAIN A REVIEW |
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION 330 (16): 1568-1580 OCT 24 2023 |
10.1001/jama.2023.19675 |
CLINICAL MEDICINE |
108 |
|
13 |
HERTHENA-LUNG01, A PHASE II TRIAL OF PATRITUMAB DERUXTECAN (HER3-DXD) IN EPIDERMAL GROWTH FACTOR RECEPTOR-MUTATED NON-SMALL-CELL LUNG CANCER AFTER EPIDERMAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR THERAPY AND PLATINUM-BASED CHEMOTHERAPY |
JOURNAL OF CLINICAL ONCOLOGY 41 (35): 5363-+ DEC 10 2023 |
10.1200/JCO.23.01476 |
CLINICAL MEDICINE |
105 |
|
14 |
MODULATING EXTRACELLULAR MATRIX STIFFNESS: A STRATEGIC APPROACH TO BOOST CANCER IMMUNOTHERAPY |
CELL DEATH & DISEASE 15 (5): - MAY 1 2024 |
10.1038/s41419-024-06697-4 |
MOLECULAR BIOLOGY & GENETICS |
89 |
|
15 |
GLOBAL BURDEN OF METABOLIC DISEASES, 1990-2021021 |
METABOLISM-CLINICAL AND EXPERIMENTAL 160: - NOV 2024 |
10.1016/j.metabol.2024.155999 |
BIOLOGY & BIOCHEMISTRY |
69 |
|
16 |
GLOBAL, REGIONAL, AND NATIONAL PREVALENCE OF ADULT OVERWEIGHT AND OBESITY, 1990-2021, WITH FORECASTS TO 2050: A FORECASTING STUDY FOR THE GLOBAL BURDEN OF DISEASE STUDY 2021 |
LANCET 405 (10481): 813-838 MAR 8 2025 |
10.1016/S0140-6736(25)00355-1 |
CLINICAL MEDICINE |
47 |
|
17 |
BURDEN OF DISEASE ATTRIBUTABLE TO HIGH BODY MASS INDEX: AN ANALYSIS OF DATA FROM THE GLOBAL BURDEN OF DISEASE STUDY 2021 |
ECLINICALMEDICINE 76: - OCT 2024 |
10.1016/j.eclinm.2024.102848 |
CLINICAL MEDICINE |
41 |
|
18 |
RHIZOMA DRYNARIAE-DERIVED NANOVESICLES REVERSE OSTEOPOROSIS BY POTENTIATING OSTEOGENIC DIFFERENTIATION OF HUMAN BONE MARROW MESENCHYMAL STEM CELLS VIA TARGETING ERA SIGNALING |
ACTA PHARMACEUTICA SINICA B 14 (5): 2210-2227 MAY 2024 |
10.1016/j.apsb.2024.02.005 |
PHARMACOLOGY & TOXICOLOGY |
35 |
|
19 |
CONSENSUS ON THE MONITORING, TREATMENT, AND PREVENTION OF LEUKAEMIA RELAPSE AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHINA: 2024 UPDATE |
CANCER LETTERS 605: - NOV 28 2024 |
10.1016/j.canlet.2024.217264 |
CLINICAL MEDICINE |
35 |
|
20 |
IMLGAM: INTEGRATED MACHINE LEARNING AND GENETIC ALGORITHM-DRIVEN MULTIOMICS ANALYSIS FOR PAN-CANCER IMMUNOTHERAPY RESPONSE PREDICTION |
IMETA 4 (2): - APR 2025 |
10.1002/imt2.70011 |
MICROBIOLOGY |
32 |
|
21 |
HARNESSING THE TUMOR MICROENVIRONMENT: TARGETED CANCER THERAPIES THROUGH MODULATION OF EPITHELIAL-MESENCHYMAL TRANSITION |
JOURNAL OF HEMATOLOGY & ONCOLOGY 18 (1): - JAN 13 2025 |
10.1186/s13045-024-01634-6 |
CLINICAL MEDICINE |
30 |
|
22 |
TRANSARTERIAL CHEMOEMBOLISATION COMBINED WITH LENVATINIB PLUS PEMBROLIZUMAB VERSUS DUAL PLACEBO FOR UNRESECTABLE, NON-METASTATIC HEPATOCELLULAR CARCINOMA (LEAP-012) : A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PHASE 3 STUDY |
LANCET 405 (10474): 203-215 JAN 18 2025 |
10.1016/S0140-6736(24)02575-3 |
CLINICAL MEDICINE |
30 |
|
23 |
THE OSTEOARTHRITIS |
NATURE REVIEWS DISEASE PRIMERS 11 (1): - FEB 13 2025 |
10.1038/s41572-025-00594-6 |
CLINICAL MEDICINE |
20 |
|
24 |
TISSUE MACROPHAGES: ORIGIN, HETEROGENITY, BIOLOGICAL FUNCTIONS, DISEASES AND THERAPEUTIC TARGETS |
SIGNAL TRANSDUCTION AND TARGETED THERAPY 10 (1): - MAR 7 2025 |
10.1038/s41392-025-02124-y |
MOLECULAR BIOLOGY & GENETICS |
11 |
|
25 |
A METALLIC ROOM-TEMPERATURE D-WAVE ALTERMAGNET |
NATURE PHYSICS 21 (5): - MAY 2025 |
10.1038/s41567-025-02822-y |
PHYSICS |
10 |
|
26 |
REGULATION OF CELLULAR SENESCENCE IN TUMOR PROGRESSION AND THERAPEUTIC TARGETING: MECHANISMS AND PATHWAYS |
MOLECULAR CANCER 24 (1): - APR 2 2025 |
10.1186/s12943-025-02284-z |
MOLECULAR BIOLOGY & GENETICS |
8 |
|
27 |
DISCOVERY OF ANTIMICROBIAL PEPTIDES WITH NOTABLE ANTIBACTERIAL POTENCY BY AN LLM-BASED FOUNDATION MODEL |
SCIENCE ADVANCES 11 (10): - MAR 5 2025 |
10.1126/sciadv.ads8932 |
BIOLOGY & BIOCHEMISTRY |
8 |
|
28 |
FIRST-LINE MOBOCERTINIB VERSUS PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH <I>EGFR</I> EXON 20 INSERTION-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER IN THE PHASE III EXCLAIM-2 TRIAL |
JOURNAL OF CLINICAL ONCOLOGY 43 (13): - MAY 1 2025 |
10.1200/JCO-24-01269 |
CLINICAL MEDICINE |
5 |
